Compare Cassava Sciences Inc (FLNA) vs Harmony Gold Mining Co. (HMY) Price & Performance

Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.

The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.

Harmony Gold Mining (HMY) trades at $15.24, up 1.67% today, with bearish technical signals from moving averages. The company shows strong fundamentals with 2024 revenue of $61.38B and net income of $8.59B, delivering a 20.06% net margin. Recent earnings show mixed results with a Q4 2025 miss but previous quarters beating expectations. The stock offers a dividend yield with a $0.31 payment scheduled for May 2026.

HMY presents value with attractive valuation ratios (P/E 9.69, EV/EBITDA 5.04) and robust profitability (ROE 32.32%). However, analyst sentiment is cautious with 70% hold ratings, and technical indicators suggest near-term pressure. Key risks include gold price volatility and Federal Reserve policy impacts, while the transition to gold-copper hybrid operations offers long-term growth potential.